WNT3A and neurogenic arthropathy: Gene expression analysis of WNT3A showed a statistically significant decrease by 89% in the Charcot group compared to the healthy controls (median = 0.1056; p < 0.0001), and a notable down-regulation by 82% when compared to T2DM patients not suffering from Charcot arthropathy (median = 0.5916; p = 0.0147).